Abstract
Ceftazidime (CAZ, SN401), a new cephalosporin antibiotic, was evaluated for its in vitro antibacteril activity and clinical effects.
MICs of CAZ for clinical isolates from urine were determined. Eight of 13 strains of E. coli were inhibited at 0.78μg/ml or lower, all 6 strains of S. marcescens, at 3.13μg/ml or lower. As to P. aeruginosa, 1 strain was inhibited at 6. 25μg/ml and 3 strains at 25μg/ml.
1g dose of CAZ was administered intravenously to 3 healthy volunteers, and serum and urine concentrations were determined. Half-life was 87.6 min. and urinary recovery up to 6 hrs. was 84.9%.
In 10 patients with complicated urinary tract infections, the clinical efficacy rate of CAZ was 80%.
No clinical side effect was observed at all.
In hematology or blood chemistry, there was no abnormality which requires withdrawal of the drug.
